Short answer
Beta Bionics, Inc. (BBNX) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). FDA clearance for Mint patch pump, enabling potential U.S. commercialization.
Beta Bionics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA clearance for Mint patch pump, enabling potential U.S. commercialization
- 510(k) submission for 3D Intelligence dosing algorithm, advancing regulatory review
- Updated corporate presentation, providing additional company and product information
Item 8.01 · Other Events
- FDA-cleared Mint expands Beta Bionics’ commercial platform, with U.S. launch targeted for Q1 2027
- Planned 2027 capacity of at least 1.5 million disposable units supports potential scale, but execution remains unproven
- Pharmacy-only launch initially reaches approximately 40% of insured U.S. lives, targeted to reach at least 50% within one year
- 3D Intelligence 510(k) submission creates regulatory catalysts for iLet 3D by year-end 2026 and Mint 3D alongside Mint launch
- Securities class action alleges iLet safety, efficacy and commercial-success misstatements, creating litigation costs and management distraction risk
Item EX-99.1 · Exhibit EX-99.1
- FDA clearance for Mint enables U.S. commercialization, targeted for Q1 2027 through the pharmacy channel
- 2027 manufacturing capacity targets at least 1.5 million disposable units, supporting potential scale-up
- 3D Intelligence submitted via 510(k); iLet 3D expected by end-2026 and Mint 3D in Q1 2027, pending clearance
- 2026 revenue guidance reduced to $121M–$126M from $131M–$136M, reflecting potential fourth-quarter deferrals up to $10M
- 2026 gross-margin guidance reaffirmed at 58.5%–59.5%; Mint expected modestly dilutive in 2027 but accretive at scale
Item EX-99.2 · Exhibit EX-99.2
- Q2’26 net sales $32.0M, gross margin 59.0%, with 69% of new starts from MDI patients
- High-30s% of Q2’26 new starts reimbursed through pharmacy, validating Beta Bionics’ lower-friction distribution strategy
- Mint patch pump FDA-cleared in September 2026, with full U.S. commercial launch targeted for Q1’27
- 3D Intelligence 510(k) submitted, targeting iLet 3D commercialization by end-2026 and Mint 3D in Q1’27
- T2D indication expansion targeted around mid-2027, potentially opening the underpenetrated primary-care and insulin-intensive T2D markets
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beta Bionics, Inc. 8-K filings
Get the next BBNX 8-K as it lands
Follow BBNX for push alerts, or ask the research agent what this filing means.